Mats Wahlstrom

Mats Wahlstrom, listed as board member, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Coherus Oncology, Inc. and TriSalus Life Sciences, Inc. We count 25 filings; the first trade dates from 18 August 2015 and the latest from 5 June 2026.

In open-market terms, that means 3 purchases worth €66k on one side and 7 sales worth €6.8M on the other. The net balance comes to €6.7M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 5 share grants and 2 option exercises.

The median purchase comes to €22k. The 3 purchases reviewed show no overlap with other insiders buying the same stock within a month.

The newest entry dates from 9 June 2026: a share grant, in Coherus Oncology, Inc. The latest purchase dates back some time: it was published 698 days ago, on 25 November 2024. Typically, a trade is published a median of 4 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.